Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners

Akebia Therapeutics, Inc. (Nasdaq: AKBA) a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler,...

AKBA : 4.27 (+1.43%)
Akebia Therapeutics Announces Collaboration Partner's Positive Top-line Results of Phase 3 Clinical Study of Riona(R) (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan

Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco, Inc. (JT) and its subsidiary Torii Pharmaceutical Co., Ltd. (Torii), reported positive top-line...

TRXPF : 23.0200 (-2.04%)
AKBA : 4.27 (+1.43%)
Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board...

TRVN : 1.06 (+0.95%)
AKBA : 4.27 (+1.43%)
ACRS : 2.23 (+2.29%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14...

AKBA : 4.27 (+1.43%)
Akebia Therapeut Has Returned 29.2% Since SmarTrend Recommendation (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on April 4th, 2019 at $7.10. In approximately 2 months, Akebia Therapeut has returned 29.15% as of today's recent price of $5.03.

AKBA : 4.27 (+1.43%)
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced...

AKBA : 4.27 (+1.43%)
Downtrend Call Working As Akebia Therapeut Stock Falls 18.5% (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on April 4th, 2019 at $7.10. In approximately 1 month, Akebia Therapeut has returned 18.45% as of today's recent price of $5.79.

AKBA : 4.27 (+1.43%)
Akebia Therapeutics (AKBA) Reports Q1 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -4.76% and -13.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AKBA : 4.27 (+1.43%)
Akebia Therapeutics: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $72.4 million in its first quarter.

AKBA : 4.27 (+1.43%)
Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATEStudies and Announces Key Executive Appointments

--Full Enrollment of Phase 3 INNO2VATEStudies; and

AKBA : 4.27 (+1.43%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted nine...

AKBA : 4.27 (+1.43%)
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, and its strategic...

AKBA : 4.27 (+1.43%)
Akebia Therapeutics to Report First Quarter 2019 Financial Results

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced...

AKBA : 4.27 (+1.43%)
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma

Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.

JNJ : 134.71 (+0.31%)
AKBA : 4.27 (+1.43%)
FGEN : 46.43 (+1.82%)
AMGN : 176.12 (+0.68%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Coherus Bioscien (CHRS , AKBA , INSM , ICPT , CARA )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AKBA : 4.27 (+1.43%)
CHRS : 18.86 (-1.92%)
INSM : 22.21 (-2.24%)
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement

The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their license agreement to sell vadadustat to...

AKBA : 4.27 (+1.43%)
GNHAF : 143.5000 (+1.77%)
Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced...

AKBA : 4.27 (+1.43%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 16...

AKBA : 4.27 (+1.43%)
Watch for Akebia Therapeut to Potentially Rebound After Falling 9.07% Yesterday

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $7.32 to a high of $7.76. Yesterday, the shares fell 9.1%, which took the trading range below the 3-day low of $8.10...

AKBA : 4.27 (+1.43%)
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders

Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) ("Knight" or the "Company"), today announced...

PTCT : 43.62 (+1.54%)
KERX : 3.36 (-2.04%)
GUD.TO : 7.45 (-0.13%)
RYTM : 20.44 (-3.49%)
AKBA : 4.27 (+1.43%)

Van Meerten Stock Picks

Advanced Micro Devices
My NASDAQ 100 Pick of the Day is the semiconductor company Advanced Micro Devices (AMD).
AMD +1.18
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar